We report an unusual case of Leigh syndrome due to the m.10191T>C mutation in the complex I gene MT-ND3. This mutation has been associated with a spectrum of clinical phenotypes ranging from infant lethality to adult onset. Despite infantile onset and severe symptoms, our patient has survived to early adulthood because of a strict dietary regimen and parental care. This patient is an extreme example of the frequently prolonged course of Leigh syndrome due to this particular mutation.
The term Leigh syndrome (OMIM 256000) was first coined to describe an infant with subacute necrotizing encephalomyopathy affecting symmetrically the basal ganglia, thalamus, and brainstem. 1 Since Denis Leigh's initial case, the syndrome has been expanded to include all progressive encephalomyopathies with radiographic evidence of bilateral focal lesions. Leigh syndrome can result from defects of pyruvate metabolism (pyruvate dehydrogenase complex deficiency) or from a multitude of mitochondrial respiratory chain defects, 2 although complex I deficiency underlies approximately one-third of these cases. 3, 4 Within mitochondria, complex I or nicotinamide adenine dinucleotide:ubiquinone oxidoreductase (EC 1.6.5.3) contributes to the proton gradient via electron transfer, powering 40% of ATP synthesis. 5 Complex I encompasses 45 subunits, 7 of which are encoded by mitochondrial DNA (mtDNA; genes MT-ND1-6) and the remainder from nuclear DNA. In 2 studies, nearly 30% of patients with complex I deficiency were found to carry pathogenic mtDNA mutation, and Leigh syndrome was the most common clinical phenotype. 6, 7 Although there are many genetic causes of both Leigh syndrome and complex I deficiency, mutations in ND genes are likely culprits.
Mutations in MT-ND3 are increasingly being recognized as common causes of complex I deficiency and Leigh syndrome. A recent review summarized 16 of the published patients harboring the m.10191T>C mutation in this gene. 8 Surprisingly, the clinical spectrum was quite broad, although most patients had childhood-onset Leigh syndrome. There was poor correlation between degree of heteroplasmy and symptom severity, indicating that nuclear or other mitochondrial risk alleles can contribute to the clinical phenotype.
Here, we describe in detail an unusual case of Leigh syndrome due to maternal inheritance of m.10191T>C MT-ND3 mutation in a woman who has reached adulthood despite infantile onset and severe symptoms.
Patient Report
This 25-year-old woman was the first child of nonconsanguineous Italian parents with no family history of motor or developmental delay. Following an uncomplicated pregnancy, delivery, and postnatal period, she had motor regression starting at 4 to 6 months. She stopped gaining weight because of poor feeding and had limited motility including eye movements, which were restricted to upward gaze. By 12 months, she had developed a dystonic posture on the right more than the left side and motor regression had worsened to the point that she could not control her head. At 17 months, she suffered her first focal clonic seizure and was started on phenobarbital. There was transient improvement of motor control followed by further loss of motor skills. Despite medication, she continues to suffer from frequent generalized tonic-clonic seizures. Currently, at age 25, she has the physical development of a prepubescent child. Although she showed no improvement on riboflavin, thiamine, biotin, or other vitamins and cofactors, through the years she continued to take phenobarbital, coenzyme Q 10 , and L-carnitine. The patient's mother and 23-yearold sister are developmentally normal with normal lactate levels.
Multiple blood lactate values were elevated (5-9 mM; normal <2.2 mM). Computed tomography (CT) of the brain in childhood demonstrated bilateral hypodensities in the lateral putamen and caudate nuclei, whereas magnetic resonance imaging (MRI) demonstrated involvement of the basal ganglia, thalamus, midbrain, and periaqueductal grey matter. Brain magnetic resonance imaging performed recently showed severe, diffuse cortical and subcortical atrophy with ventricular dilation.
Methods Tissues
From the proband, her sister, and her mother, we obtained venous blood and urinary sediment from the first morning void. We also obtained muscle tissue and skin fibroblasts from the proband and skin fibroblasts from her sister.
Histochemical and Biochemical Analysis
A right quadriceps muscle biopsy was analyzed with standard histological and histochemical stainings. 9 Respiratory chain enzyme activities were measured spectrophotometrically as previously described in a 10% muscle extract. 10 
Molecular Studies
Total DNA was extracted from blood, urinary sediment, and fibroblasts using Puregene DNA Isolation Kit reagents (Qiagen Sciences, Valencia, CA) according to the manufacturer's recommended protocol. Whole genome amplification was accomplished by REPLI-g mtDNA kit (Qiagen). Whole mitochondrial sequencing was performed by long-range polymerase chain reaction (PCR) using 3 primer sets that can amplify the entire mtDNA, using 100 ng of input DNA for each reaction. The cycling conditions for all reactions were (1) 95 C for 2 minutes; (2) 95 C for 15 seconds; (3) 68 C for 7 minutes; (4) repeat step 2 29 times; (5) final extension for 12 minutes. Direct sequencing of all mtDNA was performed in an ABI Prism 310 Genetic Analyzer using Big Dye Terminator Cycle Sequencing Reaction Kits (Perkin-Elmer Applied Biosystems, Foster City, CA) using appropriate primers. The primer that was used to sequence MT-ND3 initiated at m.10141. For restriction fragment length polymorphism analysis, mtDNA was amplified by PCR using forward and reverse primers initiating at nucleotide positions m.10161 and m.10308. In the presence of the mutation, the mismatched forward primer creates a restriction site for the RsaI endonuclease. Digestion of the 147-bp fragment harboring the mutation yields 2 fragments of 118 bp and 29 bp, whereas the wild-type fragment remains uncut. The PCR products were run through a 15% nondenaturing polyacrylamide gel and subjected to SYBR Gold Nucleic Acid Stain (Invitrogen, Carlsbad, CA) to quantify the proportion of mutant mtDNA.
Results
Histochemical analysis of muscle at age 10 months showed fiber size variability and slight increase of perimysial connective tissue. With the modified Gomori trichrome and the reduced nicotinamide adenine dinucleotide-tetrazolium diaphorase stains, there was increased intermyofibrillar granularity indicative of mitochondrial proliferation, but no typical ragged-red fibers. Ultrastructural analysis confirmed increased number of mitochondria, some of which were larger than normal and contained irregular cristae.
Biochemical studies of muscle extracts showed a moderate isolated defect of reduced nicotinamide adenine dinucleotidecytochrome c reductase (complex I) ( Table 1) .
Because no large-scale mtDNA deletions were detected (data not shown), we sequenced the entire mitochondrial genome. Of the 3 mutations identified, only m.10191T>C was predicted to be deleterious by the PolyPhen program (http:// genetics.bwh.harvard.edu//pph2/index.shtml) and had been reported in the literature (Figure 1 ). This change in the coding sequence of MT-ND3 results in the substitution at position 45 of a highly conserved serine residue by proline (p.Ser45Pro). To confirm the mutation, the region was amplified by PCR for both direct Sanger sequencing and for restriction fragment length polymorphism analysis ( Figure 2 ). The proband's asymptomatic sister and mother were also analyzed, demonstrating maternal inheritance with reduced heteroplasmy. The mutation load was 70% in the proband's fibroblasts, but only 23% in the sister's fibroblasts and it was even lower in the sister's blood and urine (16% and 19%, respectively; Table 2 ). The mother had no detectable mutant mtDNA in blood but 40% mutation load in the urine sediment. 
Discussion
Including our proband, the m.10191T>C mutation has been reported in 22 patients to date (Table 3) . 6, 8, [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] There is a vast spectrum of clinical presentations and ages at onset. Most individuals had abnormal brain imaging consistent with Leigh syndrome, but diagnoses of mitochondrial encephalomyopathy, lactic acidosis, and strokelike episodes and nonspecific encephalopathy were also given. The most common symptoms were seizures, developmental delay or regression, dystonia or spasticity, and elevated blood and cerebrospinal fluid lactate, indicating that both muscle and brain are typically affected by mitochondrial dysfunction. Of the 22 cases with this mutation, updated clinical information was obtained for 12 patients (personal communications from authors) and additional information was available about survival for a total of 17 patients. Nine of those 17 patients were deceased; of these, 6 died prior to and 3 died after 10 years of age. Eight patients are either currently alive or were at the time of publication, and 7 of 8 survived beyond 10 years. One patient had adult onset of symptoms, including epilepsy, strokes, optic atrophy, and cerebellar ataxia. 22 Thus, only 6 of 17 (or 35%) of patients harboring the m.10191T>C mutation died in childhood, whereas two-thirds survive into adolescence and occasionally beyond. This survival rate is higher than that of other complex I deficiencies, where the average age of survival is 10 months and 75% to 85% of patients die prior to 10 years. 27, 28 Our patient also has a long survival although she harbors a mutation that causes Leigh syndrome and is often lethal in infancy. Her parents sought multiple medical opinions for diagnosis and symptomatic help. After receiving a diagnosis of celiac disease, they maintained her on a gluten-free, minimal Table 2 . protein diet. As a result of their attentive care, she is still alive at 25 years of age. The substitution of serine for proline is believed to interrupt a hydrophilic transmembrane alpha helix domain that is crucial on proteomic analysis for the interaction of the major subunits of complex I and therefore for the activity of the complex. 29 Analysis of a cybrid line demonstrated that this mutation leads to a 60% reduction in complex I assembled protein, yet the functional capacity is even further reduced, suggesting that ND3 is important both for complex assembly and catalysis. 25 This particular mutation can have a better survival curve than other complex I deficiency mutations because it permits residual enzyme activity. 25 There are several conditions that may influence the phenotype diversity resulting from this mutation. Although mutation loads as measured in muscle and blood do not correlate with symptoms, it is possible that as-yet unmeasured brain heteroplasmy might contribute to phenotype severity. 8 Additionally, the m.10191T>C mutation could be modified by other mitochondrial or nuclear gene variants, as is the case for mitochondrial deafness and Leber's hereditary optic neuritis. 30, 31 Whole exome sequencing combined with population-level genetic analysis may soon lead to the discovery of such gene-gene interactions. Finally, infection, toxins, and other metabolic stressors may alter the presentation of the m.10191T>Cassociated disease symptoms. More detailed patient assessments would be necessary to determine such an effect. To date, none of these factors have been described for the m.10191T>C mutation.
Could the prolonged survival in our patient be due to the life-long administration of coenzyme Q 10 and L-carnitine? Although this appears unlikely based on the mild and anecdotal effects of these supplements in other mitochondrial diseases, this question will be answerable only after rigorous doubleblind, placebo-controlled therapeutic trials of coenzyme Q 10 and L-carnitine in mitochondrial diseases will be conducted.
Because some patients appeared to have either a de novo mutation or maternally inherited but vastly increased degree of heteroplasmy, screening for m.10191T>C as a prenatal genetic tool has limited value. 21, [23] [24] [25] When considering diagnostic screening, however, Leigh syndrome patients with complex I deficiency are more likely to harbor deleterious mutations in mitochondrial than in nuclear genes. 6, 26 As our understanding of the genetics and pathophysiology of Leigh syndrome progresses, we will hopefully be able to offer increasing symptomatic treatment and even preventive intervention such as pronuclear or spindle transfer into donor oocytes without mitochondrial mutations. [32] [33] [34] This latter option, if approved for human application, will be especially useful to our proband's asymptomatic carrier sister and other female relatives of patients who wish to avoid maternal transmission of Leigh syndrome or other mtDNA-related diseases.
